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Rationing of scarce medical resources is inevitable during a 
pandemic. Even the best-resourced countries will have inadequate 
intensive care facilities for the large numbers of patients needing 
admission and ventilation due to SARS-CoV-2 infection. Scarcity 
of resources creates the need for national governments to establish 
admission criteria that are evidence-based and fair.[1] In South Africa 
(SA), where the number of patients with COVID-19 is steadily 
increasing, this conversation is just beginning. There has been 
widespread speculation in the lay and medical media about whether 
infection with HIV or tuberculosis (TB) may amplify the risk of 
adverse COVID-19 outcomes.[2] Conversely, some have proposed 
that HIV-infected patients may be protected against infection with 
SARS-CoV-2 by the antiviral effect of antiretroviral therapy (ART),[3] 
especially the protease inhibitor, ritonavir-boosted lopinavir (LPV/r). 
Unfortunately, as demonstrated by a recent systematic review, such 
optimism is likely to be unfounded.[4] The review included two 
randomised trials and 21 observational studies that reported on the 
use of LPV/r for the treatment of COVID-19, severe acute respiratory 
syndrome (SARS) and Middle East respiratory syndrome (MERS) 
and concluded that there was no evidence that LPV/r prevented 
infection or improved clinical outcomes. In addition, many are 
sceptical about the potency of LPV/r against coronavirus proteases. [5] 
Since the body of evidence is limited, several randomised trials are 
ongoing to assess the safety and efficacy of ART for the treatment of 
COVID-19.
In these uncertain times, it is important not to lose sight of clinical 
evidence. Given the large number of people living with HIV (PLWH) 
and TB in SA, the inclusion of these diseases as comorbidities 
relevant to intensive care unit (ICU) admission triage criteria should 
be carefully examined. In this article, we briefly discuss the risk 
factors and proposed immunopathological mechanisms of adverse 
outcomes of COVID-19 and how these may be affected by HIV and 
TB. We further describe the clinical profiles of patients with HIV and 
TB with regard to COVID-19 risk factors and conclude by reviewing 
the outcome of cases of HIV/SARS-CoV-2 co-infected patients 
reported in the medical literature.
This is the first in a series of two articles. The present article serves 
in part to provide the scientific and medical basis for a subsequent 
article outlining the ethicolegal implications of limiting ICU access.
Predictors of adverse outcomes
South Africa is (in)famous for social and economic inequality, and 
this inequality is strongly reflected in healthcare provision. The 
country has, in effect, a two-tier system – a well-resourced and 
minimally burdened private, fee-paying system, and an under-
resourced, overburdened public system that is essentially free at 
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the point of care. These inequalities in our healthcare system may 
affect the outcomes of patients with COVID-19. Regardless of 
the healthcare system, critical care is expensive, labour-intensive 
and specialised. As a scarce resource, it has to be rationed, with 
access determined by evidence-based clinical criteria and ethicolegal 
considerations. Internationally, it is recommended that access be 
informed by a holistic assessment of the patient using the Clinical 
Frailty Scale as appropriate, together with considerations of the 
severity of the acute illness, comorbidities and underlying health 
conditions, and how these will impact on the desired outcome.[6] The 
comorbidities most commonly associated with an adverse outcome 
during the COVID-19 pandemic are hypertension, diabetes mellitus, 
chronic obstructive pulmonary disease (COPD), malignancy[7] and 
coronary heart disease.[8] Multiple comorbidities, advanced age and 
smoking have also been identified as risk factors for poor outcome.[9]
Advanced age is the clinical variable with the strongest associated 
risk for hospitalisation, ICU admission and mortality from COVID-
19.[9] The pathophysiological mechanisms underlying this risk are 
under intense investigation. A popular working hypothesis is that 
ageing is associated with thymic involution, leading to a significant, 
continuous decrease in precursor CD4+ and CD8+ T-cells, which 
are vital for antiviral responses.[10] This effect of ageing is more 
pronounced in men than women.[10] Consequently, older people, 
and men in particular, are at risk for worse outcomes following 
infection with a variety of viruses – including West Nile virus, HIV, 
influenza and SARS.[11-13] In addition, ageing is characterised by a 
senescence-associated secretory phenotype, with increased levels 
of proinflammatory mediators and matrix-degrading molecules 
contributing to a state of chronic, systemic, low-grade inflammation 
called ‘inflammaging’.[14]  Older age has been shown to be a major 
risk factor for developing acute respiratory distress syndrome,[15] the 
most common cause of death in patients with COVID-19,[16] possibly 
secondary to high levels of underlying inflammation.
Clinical profile of HIV-infected 
patients
The effects of HIV infection on the immune system are in many ways 
similar to those observed during ageing. In the context of prolonged, 
untreated HIV infection, naive CD4+ T-cell populations decrease. 
In addition, a preponderance of T-cells exhibit an exhausted and 
activated profile,[17] eventually leading to immunosenescence and 
inflammaging.[18] Therefore, both ageing and untreated HIV infection 
lead to significant T-cell dysfunction and inflammation, increasing 
the risk of adverse outcomes following viral infection. Initiation of 
ART and suppression of HIV replication increase the proportion 
of circulating naive T-cells[17] and significantly improve, but do not 
normalise, the risk of infection with a wide range of pathogens.[19]
In 2018 there were ~7.7 million PLWH (~14% of the total 
population) in SA, with an estimated 4.8 million (or 62%) on ART, 
and 54% of PLWH were virally suppressed.[20] SA has a relatively 
young population, with a median age of 27 years; this is also 
reflected in the age of people starting ART, which was 38 years in 
2017.[21] However, in 2015, 14% of patients in HIV care were aged 
≥50 years, and this figure is likely to have increased since then.[22] 
Keeping in mind that comorbidities are often under-reported,[23] non-
communicable diseases are common in PLWH, with hypertension 
being the most prevalent.[24] In addition, smoking is common in 
males with HIV (34% in one cross-sectional survey), and less so in 
females.[25]
Untreated HIV and low CD4+ counts have been suggested as 
possible risk factors for COVID-19.[26] Approximately 37% of PLWH 
in SA initiate ART at a CD4+ count <200 cells/µL, and they have 
a higher mortality,[21] especially from infection with influenza and 
unspecified severe respiratory tract infections,[27] than individuals 
with a higher CD4+ count. Mortality in the first year after ART 
initiation is highest in those with a CD4+ count <50 cells/µL 
(19.54/100 person-years), and decreases significantly above this level 
(CD4 >200 cells/µL = 4.01/100 person-years).[28] After 48 months 
of ART, irrespective of the starting CD4+ count, mortality rates 
approximate those of HIV-negative people.[28]
Despite the widespread availability of ART, up to 75% of HIV-
related admissions to hospitals in SA are of patients with advanced 
disease and low CD4+ counts (CD4+ T-cell counts <200 cells/µL).[29] 
The primary reason for an ICU admission in PLWH is a respiratory 
illness. In-hospital mortality is high in PLWH who are admitted 
to intensive care with a World Health Organization (WHO) stage 
IV-defining illness, lower CD4+ counts (<100 cells/µL) and higher 
APACHE II scores, and in those who need inotropic support or 
renal replacement therapy.[30] The following clinical six-point scoring 
system has been proposed to predict mortality in PLWH admitted to 
intensive care, with one point allocated to each of the following: (1) 
an AIDS-defining illness; (2) CD4+ <50 cells/µL; (3) extrapulmonary 
TB; (4) Pneumocystis jirovecii pneumonia (PCP); (5) septic shock; 
and (6) renal dysfunction.[31] In a retrospective validation study, 
>80% of patients with a score of 3 died, and no patient with a score 
of 4 survived.[31]
Clinical profile of TB-infected 
patients
SA is one of eight countries accounting for two-thirds of the global 
TB burden.[32] It has the highest burden of HIV co-infected cases 
globally: ~59% of TB patients with known HIV status are HIV-
positive.[32] Men are more prone to infection (as demonstrated by 
a female-to-male ratio of 0.72), particularly between the ages of 25 
and 54 years, with 33 - 44-year-olds having the highest incidence.[33] 
TB and COVID-19 share many of the same symptoms, which could 
complicate timely diagnosis. They also share risk factors for severe 
disease, most notably smoking and diabetes mellitus, estimated to 
contribute ~7.6% and 3.1% to global TB cases.[32]
TB is reported to be a cause of non-HIV-associated CD4+ 
lymphopenia, with a recent meta-analysis demonstrating a low 
CD4:CD8 ratio in peripheral blood of TB patients.[34] On the other 
hand, increased levels of inflammation have been described in 
diabetic patients with TB, presumably secondary to hyperactive 
T-cell responses,[35] leading to lung damage, cavitation and enhanced 
transmission.[36] Whether these factors could predispose patients 
to SARS-CoV-2 infection is unknown. What is widely believed, 
however, is that people who have post-TB chronic lung disease may 
be at increased risk of more severe COVID-19.[37]
The mortality rate of HIV/TB co-infected patients is nearly double 
that of TB monoinfected patients (73 v. 37/100 000).[32] Approximately 
3% of confirmed TB cases in SA are drug resistant, which is associated 
with a high mortality risk – 39% in one large retrospective cohort 
study.[38,39] Mortality of multidrug-resistant (MDR) TB has decreased 
dramatically since the introduction of injectable-free regimens 
containing bedaquiline,[40] although untreated HIV co-infection 
remains a significant risk factor for mortality in MDR TB.[38] The 
role of HIV co-infection is also clear in the scoring system proposed 
for predicting mortality in people admitted to intensive care with 
TB. The six factors are: (i) HIV co-infection with a CD4+ count 
<200 cells/µL; (ii) a raised creatinine level; (iii) diffuse parenchymal 
infiltrates/miliary pattern on chest radiograph; (iv) absence of TB 
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treatment on admission; (v) septic shock; and (vi) a low arterial 
partial pressure of oxygen/fractional inspired oxygen ratio.[41] People 
admitted to intensive care with PCP are at a dramatically increased 
risk of mortality if they are co-infected with TB (TB co-infected PCP 
admission relative to PCP only for 90-day mortality outcomes = 
adjusted odds ratio of 82).[42]
International experience
There is scant evidence to help clinicians understand the risks of 
COVID-19 in PLWH. The European AIDS Clinical Society and 
the British HIV Association have issued a joint statement affirming 
that there is currently no evidence to suggest that HIV infection 
alone predisposes to an increased risk of infection with SARS-
CoV-2, or worse outcomes for COVID-19.[43] Looking at past 
coronavirus epidemics, there is a case report of an HIV-positive man 
infected with MERS coronavirus who had successful resolution of 
multilobar pneumonia following antiviral therapy with interferon 
and ribavirin. [44] Of note, this patient had a critically low CD4+ 
count of 58 cells/µL and was receiving prednisone when admitted for 
MERS, after recovering from a recent admission for PCP.[44] A current 
case report showed that a person who was HIV/HCV co-infected 
produced a weak SARS-CoV-2 antibody response in the context of 
persistent negative diagnostic polymerase chain reactions following 
hospital admission for fever and pneumonia.[45] Furthermore, a 
community survey of 1 178 PLWH in Wuhan, China, confirmed that 
their COVID-19 incidence was similar to the general population. 
In the 8/1 178 confirmed cases, age (and not CD4+ count, HIV 
viral load or ART) was associated with severe disease.[46] These data 
suggest that age and comorbidity are likely to be more important 
factors to consider than HIV per se.
A recent COVID-19 case series reported that 5/543 (0.92%; 95% 
confidence interval 0.39 - 2.14) patients admitted to a hospital in 
Spain were HIV-infected. Of these 5 patients, 4 were virologically 
suppressed, with CD4+ counts >400 cells/μL, and 1 patient, a late 
presenter, had a CD4+ count of 13 cells/μL with an HIV viral load 
of 45 500 copies/mL. Two patients had upper respiratory tract 
infections, and 3 had viral pneumonia. Of the latter, 2 required 
ventilatory support; one was a 31-year-old with advanced AIDS 
and the other was a 49-year-old with hypothyroidism as his only 
additional comorbidity. None of the patients died, although the 
49-year-old was still in the ICU at the time of writing. The authors 
highlight the need to exclude other pathogens that could present in a 
similar way to SARS-CoV-2 in late presenters.[47]
There is even less information available on the impact of TB 
on COVID-19. The WHO has issued a statement that co-infected 
patients may be more susceptible to infection, with the presence 
of communal risk factors, namely diabetes mellitus and COPD, 
playing a major role.[37] A recent observational case-control study of 
36 confirmed COVID-19 cases from China, available as a preprint, 
reported that TB appears to increase susceptibility to, and severity 
of, COVID-19. While these data still need to be peer reviewed and 
validated in larger studies, they underscore the need to routinely verify 
the TB infection status of COVID-19 patients.[48] Interestingly, during 
the SARS pandemic, two SARS-infected patients who recovered were 
reported to have developed active TB after recovering from the viral 
infection,[49] raising the question of whether SARS-CoV-2 infection 
will trigger TB reactivation in latent carriers. Epidemiological data 
from SA indicate that annual influenza epidemics are followed by 
a peak in incidence for pulmonary TB and invasive pneumococcal 
disease.[50] We may have to prepare for an increase in the incidence of 
TB or pneumococcal disease after COVID-19 has receded.
Conclusions
At this early stage of the pandemic, there is no evidence suggesting 
that HIV or TB infection on their own predispose to an increased 
risk of infection with SARS-CoV-2 or worse outcomes for COVID-
19. However, both conditions have well-known poor prognostic 
indicators, and these should be considered when patients are assessed 
for eligibility for ICU admission. Persons at the highest risk of dying 
from COVID-19 in SA are expected to be those aged >60 years 
with multiple comorbidities. HIV-positive patients are likely to be 
most at risk when they are not yet on ART and have CD4+ counts 
<50 cells/µL. Co-infections with Cryptococcus neoformans, P. jirovecii 
or Mycobacterium tuberculosis would also be strong predictors of 
in-hospital mortality in severe COVID-19. Considering the current 
evidence and in light of the probable future demand on ICU care, 
we recommend that protocols for determining eligibility to ICU do 
not include the presence of HIV and TB per se as exclusion criteria, 
but rather make use of validated disease-specific scoring systems. As 
the pandemic unfolds in SA, it is important to stay updated with the 
emerging evidence and review this recommendation if the balance of 
evidence changes.
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